A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Recruiting now

Conditions studied: Pancreatic Cancer, Pancreas Cancer

In brief

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Key facts

Study ID

NCT07612046

Run by

Memorial Sloan Kettering Cancer Center

People needed

79

Starts

2026-05-20

Expected to finish

2028-05-20

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
• Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
• Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
• Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
• For this pilot MRP study, we will additionally apply the following Criteria:
• Consents to follow-up contact
• US residents
• Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
• No metallic artifacts covering the pancreas on prior MRCP
• Scheduled for endoscopic ultrasound
• No new contraindications for MRI (e.g. new MR unsafe device)
• No history of claustrophobia or use of anxiolytic on prior MRI
• No history of abdominal surgery that may affect interpretation of either EUS or MR
• No medical conditions that confers increased and/or unacceptable risk for anesthesia
• We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.
• Documentation of Disease
• o No pathologic confirmation of disease is necessary
• Definition of Disease N/A
• Required Organ Function N/A

Where it is running

• Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Monmouth (Consent only) — Middletown, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Suffolk-Commack (Consent only) — Commack, New York, United States (enrolling)
• Memorial Sloan Kettering Westchester (Consent only) — Harrison, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.